louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00292006: Computerized Tomography to Help Diagnosis Pediatrics Scaphoid Fractures.
Official title: The Efficiency of Computerized Tomography to Aid in the Diagnosis of Pediatrics Scaphoid Fractures
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Scaphoid Bone
Fracture
Keywords: clinical scaphoid fracture
pediatric
Lead sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sponsor class: OTHER
First posted: 2006-02-15
Enrollment: 0
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to find out whether computerized tomography will be better than plain radiographs in determining pediatrics scaphoid fractures.

Detailed description: Background: The use of plain radiograph in the detection of pediatrics scaphoid fractures has low specificity and sensitivity. Patients with documented anatomical snuffbox tenderness and negative plain radiographs are casted in thumb spica casts and seen by a pediatrics orthopedics surgeon. However few patients with clinical scaphoid fractures have documented scaphoid fractures, with the most common injury of soft tissue injury to the surrounding tissues. The use of CT scan to detect scaphoid fractures is not well documented and may be an appropriate substitute for plain radiographs.

Hypothesis: CT scan of the wrist will have higher sensitivity and specificity in detecting pediatrics scaphoid fracture than plain radiographs.

Eligibility criteria: Inclusion Criteria:

* Pain in anatomical snuffbox, Negative radiographs, less than 18 years old, older than 6 years old, injury less than 1 week old and provision of informed consent

Exclusion Criteria:

* Previous injury to scaphoid bone, other injuries on the same extremity, vascular injury present at the injury site, fracture seen on initial radiographs, injury \>1 week old, inability for patient to comply with rehabilitation or form completion, likely problems in maintaining patient follow-up

Primary outcomes:
measure: Fracture diagnosis
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: Canada
facility: London Health Sciences Center Victoria Hospital
state: Ontario
Study officials:
affiliation: Western University, Canada
name: Tim P Carey, MD, FRCSC
role: STUDY_CHAIR
References:
citation: Temple CL, Ross DC, Bennett JD, Garvin GJ, King GJ, Faber KJ. Comparison of sagittal computed tomography and plain film radiography in a scaphoid fracture model. J Hand Surg Am. 2005 May;30(3):534-42. doi: 10.1016/j.jhsa.2005.01.001.
citation: Breederveld RS, Tuinebreijer WE. Investigation of computed tomographic scan concurrent criterion validity in doubtful scaphoid fracture of the wrist. J Trauma. 2004 Oct;57(4):851-4. doi: 10.1097/01.ta.0000124278.29127.42.
Clinical trial NCT03199599: Prognostic PET/CT Model in Non Small Cell Lung Cancer
Official title: Prognostic Positron Emission Tomography/Computed Tomogrpahy Model in Non Small Cell Lung Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Non Small Cell Lung Cancer
Keywords: PET/CT
image processing
outcome
Lead sponsor: Poitiers University Hospital
Sponsor class: OTHER
Collaborators: name: Institut National de la Santé Et de la Recherche Médicale, France
First posted: 2017-06-27
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 150 patients with Non small cell lung cancer undergoing initial staging FDG PET/CT

Brief summary: Prospective validation of a prognostic model based on advanced PET/CT image analysis in non small cell lung cancer

Detailed description: Validation on a prospective cohort of patient of a predictive model for survival based on image derived parameters

Eligibility criteria: Inclusion Criteria:

* non small cell lung cancer
* initial fluorodeoxygluoces (FDG) PET/CT before treatment

exclusion criteria:

* none

Primary outcomes:
measure: validation of a multiparametric PET/CT prognostic model
timeFrame: 18 months
Secondary outcomes:
Other outcomes:
Locations:
city: Poitiers
country: France
facility: Chu Poitiers
Study officials:
affiliation: Institut National de la Santé Et de la Recherche Médicale, France
name: MATHIEU HATT, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01544699: Impact of Non-invasive Brain Stimulation on Motor Recuperation
Official title: Impact of Non-invasive Brain Stimulation on Motor Recuperation
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: NA
Conditions: Stroke
Keywords: stroke
Lead sponsor: University Hospital of Mont-Godinne
Sponsor class: OTHER
First posted: 2012-03-06
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: no change
Primary purpose: TREATMENT

Brief summary: tDCS (transcranial direct current stimulation) will be used in chronic stroke patients to improve a variety of functions with superior or inferior limb.

Detailed description: tDCS will be used in chronic stroke patients to improve a variety of functions such as motor functions with superior or inferior limb.

tDCS will be applied in a placebo-controlled, double-blind, randomised fashion. Behavioural data will be collected before and after tDCS, as well as brain functional imaging data.

Eligibility criteria: Inclusion Criteria:

* stroke with at least slight deficit in superior or inferior limb

Exclusion Criteria:

* epilepsy
* contraindication to tDCS and/or to fMRI
* presence of metal in the head
* inability to understand/complete behavioural tasks
* chronic intake of alcohol or recreative drugs
* major health condition
* presence of pacemaker
* pregnancy

Primary outcomes:
measure: change in motor function before/after tDCS
timeFrame: Baseline (>6 months after stroke), immediately after intervention (30min of tDCS), 10-20-30-40-50-60 min after intervention; long-term after intervention : 1-2-3-4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Yvoir,
country: Belgium
facility: Department of Neurology, CHU Mont-Godinne
state: Namur,
Study officials:
References:
citation: Elsner B, Kugler J, Pohl M, Mehrholz J. Transcranial direct current stimulation (tDCS) for improving activities of daily living, and physical and cognitive functioning, in people after stroke. Cochrane Database Syst Rev. 2020 Nov 11;11(11):CD009645. doi: 10.1002/14651858.CD009645.pub4.
Clinical trial NCT02164799: The Epidemiology and Approach to Differentiating Etiologies of Shock in the Emergency Department
Official title: Establishing a Tool to Increase the Accuracy of Emergency Physicians Diagnosing Etiologies of Shock
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Undifferentiated Shock
Keywords: Shock
Predicting diagnosis
Predicting adverse outcomes
Lead sponsor: Beth Israel Deaconess Medical Center
Sponsor class: OTHER
First posted: 2014-06-17
Enrollment: 2500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Emergency Department patients

Brief summary: The Shock Tool study is designed to improve the clinical evaluation for differentiating shock in the emergency department. The goal of this study is to evaluate and improve the accuracy of physicians differentiating causes of shock.

Detailed description: Specific Aim #1: To study the epidemiology of shock in the emergency department Hypothesis 1: We will better understand shock states if we determine shock etiology among patients presenting to the emergency department in a carefully conducted observational prospective study.

Specific Aim #2: To determine the accuracy of physician diagnosis for the underlying etiology of shock.

Hypothesis 2: Physician assessment of the underlying cause of shock is challenging and often inaccurate in the early stages of care in the emergency department.

Specific Aim #3: To optimize the evidence-based approach to assist in the diagnosis of shock etiology from elements readily available when a patient demonstrates shock physiology in the Emergency Department.

Hypothesis 3: An evidenced-based, standardized approach to clinical decision making integrating elements of the history, physical exam, and early testing will improve a physician's ability to accurately differentiate etiologies of shock.

Eligibility criteria: Inclusion Criteria:

* Age 18 years or great
* For pre-shock cohort: HR \> 130, RR\>24, Shock index \> 1, lactate \> 4.0mmol/L, SBP \< 90mm/hg)
* For shock cohort: persistent blood pressure \<90mm/hg after resuscitation

Exclusion Criteria:

* seizure
* isolated atrial fibrillation with discharge after rate control achieved
* discharged from the emergency department
* intoxication or withdrawal

Primary outcomes:
measure: Etiology of Shock
timeFrame: Retrospectively, 1 month after enrollment
Secondary outcomes:
measure: In hospital mortality
timeFrame: This measure will be assessed at the time of physician review after discharge from hospital, on average 2 months after initial ED visit.
Other outcomes:
measure: Deterioration
timeFrame: This measure will be assessed at the time of physician review after discharge from hospital, on average 2 months after initial ED visit.
Locations:
Study officials:
References:
Clinical trial NCT01109199: Effects of a Dietary Fibre Supplementation of a Low Calorie Diet on Appetite and Body Weight
Official title: A Randomized, Double Blind, Placebo Controlled Trial Evaluating the Effects of a High Viscosity Dietary Fibre (PGX) Supplementation of a Low Calorie Diet on Appetite and Body Weight, in Overweight and Moderately Obese Females
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Appetite Suppression
Weight Loss
Keywords: viscous
fibre
polysaccharide
appetite
hunger
satiety
weight management
Lead sponsor: Canadian Center for Functional Medicine
Sponsor class: OTHER
Collaborators: name: University of British Columbia
name: InovoBiologic Inc.
First posted: 2010-04-23
Enrollment: 20
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This 18 week, randomized, double blind, placebo controlled trial will examine the effects of thick dietary fibre (PGX) supplementation of a low calorie diet (LCD) on appetite, weight loss, body composition, and compliance in overweight and moderately obese female.

The investigators believe that 15 grams/day PGX supplementation of a low calorie diet over a 14-weeks period will elicit a better appetite score (e.g. reduced hunger) compared to the rice flour supplementation of the LCD.


Eligibility criteria: Inclusion Criteria:

* BMI 25 - 35 Kg/m2

Exclusion Criteria:

* Medications and supplements that affect appetite
* Known diabetes
* Contraindications to LCD
* Any other medical, social or geographic condition, which, in the opinion of the investigator would not allow safe completion of the protocol.

Primary outcomes:
measure: The difference in appetite score assessed from appetite Visual Analog Scale
timeFrame: 18 weeks
Secondary outcomes:
measure: Change in weight (kilograms)
timeFrame: 18 weeks
measure: Change in percentage of body fat
timeFrame: 18 weeks
Other outcomes:
Locations:
city: Coquitlam
country: Canada
facility: Canadian Center for Functional Medicine
state: British Columbia
city: Coquitlam
country: Canada
facility: Canadian Center for Functional Medicine
state: British Columbia
Study officials:
affiliation: Canadian Center for Functional Medicine
name: Michael R Lyon, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00933699: Dermacyd PH_DESILSTY_FL (Lactic Acid) - Acceptability - Stay on Floral.
Official title: Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynaecological Follow up - Dermacyd PH_DESILSTY_FL (Lactic Acid).
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hygiene
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2009-07-07
Enrollment: 32
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Primary Objective:

To prove the safety of the gynaecological formulation in normal conditions of use.


Eligibility criteria: Inclusion criteria:

* Integral vaginal mucosa in the product analysis region
* Use the same category cosmetics products
* Willingness in following the study procedures and to be present in the clinic at the days and scheduled time;

Exclusion criteria:

* Use of Anti-inflammatory, immunossupression or antihistaminics drugs
* Allergic or atopic history to cosmetics products
* Cutaneous active disease (local and/or general) in the evaluated area
* Disease which can cause immunosuppresion, such as diabetes, HIV
* Endocrinology pathology such as thyroid gland, ovary and adrenal gland
* Intensive solar exposure until 15 days before evaluation
* Gynecological treatment until four weeks before the study
* Other reason considered by the investigator as a reason for not being included.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: The absence of irritation and the good acceptability will be evaluated using one specific scale which describes the intensity of the reaction.
timeFrame: From the treatment start to the end of the study (treatment period 21 days)
Secondary outcomes:
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Sanofi-Aventis Administrative Office
Study officials:
affiliation: Sanofi
name: Jaderson Lima
role: STUDY_DIRECTOR
References:
Clinical trial NCT01270399: Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer
Official title: Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: The Combined Effect of Hsp90 Inhibitor and HDAC/Proteasome Inhibitors on Lung Cancer Cell Fate and ER-Golgi Homeostasis Will be Examined.
Lead sponsor: Meir Medical Center
Sponsor class: OTHER
First posted: 2011-01-05
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: lung tissue with primary malignant neoplasm

Brief summary: Lung cancer remains the most common cause of cancer-related death in the world. The major advances in treatment of lung cancer have brought only minor improvements in survival therefore novel systemic treatment methods are urgently needed.

Protein levels are regulated by the protein homeostasis network that generates and protects the protein fold (ER and Golgi included).

The heat shock protein 90 (Hsp90) is an essential molecular chaperon involved in the posttranslational folding and stability of proteins. Hsp90 inhibition leads to accumulation of unfolded proteins and ER stress. The therapeutic efficacy of such inhibition may be augmented by co-administering it with other drugs that disrupt ER-Golgi homeostasis like histone deacetylase (HDAC) or proteasome inhibitors. ER-Golgi homeostasis disruption affects a wide network of proteins and pathways as such affords a systemic target. Thus, the investigators aimed to examine the effect of combined treatment of Hsp90 antagonist with proteasome or HDAC inhibitors on human lung cancer cell lines and primary cells.


Eligibility criteria: Inclusion Criteria:

* PATIENTS WITH PROVED DIAGNOSIS OF LUNG CARCINOMA THAT ARE CANDIDATS FOR RADICAL SURGICAL TREATMENT

Exclusion Criteria:

* PATIENTS WITH SUSPICION FOR LUNG CARCINOMA WITHOUT PATHOLOGYCAL DIAFNOSIS BEFORE SURGERY

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Kfar Saba
country: Israel
facility: Meir Medical Center
Study officials:
References:
Clinical trial NCT05682742: Clinical Investigation of the da Vinci Surgical System
Official title: A Prospective, Multicenter Clinical Investigation of the da Vinci Surgical System
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Thymoma
Mediastinal Tumor
Gynecologic Disease
Gynecologic Cancer
Pelvic Organ Prolapse
Prostate Disease
Prostate Cancer
Inguinal Hernia
Ventral Hernia
Obesity, Morbid
Lead sponsor: Intuitive Surgical
Sponsor class: INDUSTRY
First posted: 2023-01-12
Enrollment: 53
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This prospective, multicenter, single-arm study is being conducted to confirm safety, effectiveness, and usability of da Vinci Surgical System in performing robotic-assisted surgical procedures.


Eligibility criteria: Pre-operative Inclusion Criteria:

* Age 21 years or older
* Per study Investigator's discretion, subject is a suitable candidate to undergo multiport robotic-assisted surgery for the study specified procedure as a primary procedure

Pre-operative Exclusion Criteria:

* Subject is pregnant or suspected to be pregnant or breastfeeding
* Subject has any other condition or personal circumstance that, in the judgment of the Investigator, might interfere with the collection of complete quality data
* Subject is currently participating in or has participated in a study of an investigational agent or a significant risk investigational device study within the past 6 months
* Subject belongs to vulnerable population.
* Subject is contraindicated for anesthesia or surgery
* Subject has had previous neoadjuvant therapy, previous chemotherapy, immunotherapy, and/or radiation therapy for treatment of the cancer to be resected within the past 6 months

Primary outcomes:
measure: Incidence of conversion
timeFrame: Intra-operative
Secondary outcomes:
measure: Incidence of adverse events
timeFrame: 30-day follow-up
Other outcomes:
Locations:
city: Orlando
country: United States
facility: Orlando Health, Inc.
state: Florida
city: Lansing
country: United States
facility: Sparrow Health System
state: Michigan
city: Ridgewood
country: United States
facility: The Valley Hospital
state: New Jersey
city: Columbus
country: United States
facility: The Ohio State University Wexner Medical Center
state: Ohio
Study officials:
References:
Clinical trial NCT04287842: Impact if Desflurane Preconditioning on the Content of the Phospho-GSK-3b in the Rat's Neurons in the Model of I/R
Official title: Neuroprotective Effect of Desflurane in the Experimental Study: the Impact if Desflurane Preconditioning on the Content of the Phosphorylated Form of GSK-3b in the Neurons of the Rat's Brain in the Model of Ischemia/Reperfusion
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Heart Arrest
Keywords: desflurane
preconditioning
Lead sponsor: Negovsky Reanimatology Research Institute
Sponsor class: OTHER_GOV
First posted: 2020-02-27
Enrollment: 0
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Endpoint implementation of reactions initiated by ischemia is the mitochondrial transition pore permeability. Mitochondria pores opening results in a release of factors triggering apoptosis primarily the cytochrome С Inhibition of the pores opening protects ischemic damage of the cells. The key enzyme regulating the mitochondrial permeability transition pore is GSK-3b: the phosphorylation of the enzyme inactivates the enzyme and prevents pore opening. Aim of studi is to determine content of the phosphorylatcd GS K-3b in neurons of rat brain in the model of total tschemia/reperfusion.

Detailed description: Endpoint implementation of reactions initiated by ischemia is the mitochondrial transition pore permeability. Mitochondria pores opening results in a release of factors triggering apoptosis. primarily the cytochrome С Inhibition of the pores opening protects ischemic damage of the cells. The key enzyme regulating the mitochondrial permeability transition pore is glycogen synthase-kinase 3b (GSK-3b): the phosphorylation of the enzyme inactivates the enzyme and prevents pore opening. We have shown in previous study that preconditioning with sevoflurane increases the content of the phosphorylated form of 6SK-3b and protects the mitochondria of neurons in rats brain during ischemia/reperfusion. Aim of studi is to determine content of the phosphorylated GS K-3b in neurons of rat brain in the model of total ischemia/reperfusion influenced by: 1 MAC desflurane vs control group; 1 MAC desflurane vs 1 MAC sevoflurane and 1 MAC desflurane vs training ischemia.

Eligibility criteria: Inclusion Criteria:

* breeding albino male rats weigh from 180 to 240 g

Exclusion Criteria:

* N/A

Primary outcomes:
measure: total GSK-3b and phosphorilated (pGSK-3b)
timeFrame: after 15 minutes of exposition
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: V. Negovskij Reanimatology Research Institute RAMS
name: Valery Likhvantsev, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01274442: Impact of Genetic Polymorphisms on Dental Implant Loss
Official title: A Case-control Study on the Impact of Genetic Polymorphisms on Dental Implant Loss.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Patients Treated by Means of 1 or More Dental Implants
Keywords: dental implant
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2011-01-11
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Patients that may participate in this case-control study underwent dental implant surgery in the University Hospital in Ghent in 2004-2007.

According to one of our recent papers based on this patient group, 34/461 patients lost one or more implants. The goal is to invite these 34 patients, to update the anamnesis, to perform a brief clinical oral examination and to have a blood sample. The latter is necessary to identify relevant genetic polymorphisms of the patient that are associated with implant loss. Among the remaining patients that did not lose implants, another 34 'controls' will be invited for the same examinations.


Eligibility criteria: Inclusion Criteria:

* Dental implant surgery in the University Hospital in Ghent in 2004-2007.
* Case: dental implant loss
* Control: no dental implant loss

Exclusion Criteria:

-

Primary outcomes:
measure: genetic polymorphisms associated with implant loss
timeFrame: after 3 to 6 years
Secondary outcomes:
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: University Hospital Ghent
Study officials:
affiliation: University Hospital, Ghent
name: Hugo De Bruyn, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: